Mayne Pharma Group Limited announced that the US Food and Drug Administration (FDA) has approved the trade name LEXETTE™ for the approved drug halobetasol propionate foam, 0.05%. LEXETTE is a new formulation of halobetasol, a potent topical corticosteroid indicated for the treatment of plaque psoriasis in adult patients. The FDA approved halobetasol foam in May 2018 and Mayne Pharma made the product available to US patients before it received a trade name. The product is now available under the trade name LEXETTE. Plaque psoriasis affects approximately 7.5 million Americans with potent topical corticosteroids prescribed to approximately 80% of psoriasis patients diagnosed. LEXETTE is part of the USD 600 million potent topical corticosteroid market for which 8 million prescriptions are written annually.